2002
DOI: 10.1185/030079902125000787
|View full text |Cite|
|
Sign up to set email alerts
|

Treatment with Atorvastatin to the National Cholesterol Educational Program Goal Versus 'Usual' Care in Secondary Coronary Heart Disease Prevention

Abstract: Long-term treatment of CHD patients with atorvastatin to achieve NCEP lipid targets significantly reduces total and coronary mortality, coronary morbidity and stroke, in comparison to patients receiving 'usual' medical care. Treatment with atorvastatin is well tolerated and cost-effective.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
192
0
11

Year Published

2003
2003
2018
2018

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 471 publications
(207 citation statements)
references
References 24 publications
4
192
0
11
Order By: Relevance
“…We determined the target dose by referring to the cholesterollowering equivalent dose 21,36 as well as the dose tested in the largescale RCTs of each statin for long-term cardiovascular prevention. 1,2,5,8,[37][38][39][40] The target dose was set as 10 mg for atorvastatin and 40 mg for the other statins. The binary variable "at or above target dose" was subsequently adjusted in the Cox model.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…We determined the target dose by referring to the cholesterollowering equivalent dose 21,36 as well as the dose tested in the largescale RCTs of each statin for long-term cardiovascular prevention. 1,2,5,8,[37][38][39][40] The target dose was set as 10 mg for atorvastatin and 40 mg for the other statins. The binary variable "at or above target dose" was subsequently adjusted in the Cox model.…”
Section: Methodsmentioning
confidence: 99%
“…[1][2][3][4][5][6][7][8] Although these trials have significantly influenced post-AMI treatment, [9][10][11][12] it remains unclear whether all statins are equally effective in preventing recurrent AMI and death. Drugs in the same class are generally thought to be therapeutically equivalent because of similar mechanisms of action (class effect).…”
Section: Researchmentioning
confidence: 99%
“…18 In the LIPID study, 19 the relative risk reduction was 24% in all patients and 19% in patients with DM, whereas 51% of all patients and 58% of diabetic patients had relative risk reduction in the GREACE study. 20 In the present study, patients with DM displayed better improvement over time than patients without DM. This could potentially be due to enhanced therapeutic goals among diabetic patients, enhanced monitoring of diabetic patients and enhanced care treatment with care management, or a combination of factors.…”
Section: Discussionmentioning
confidence: 51%
“…These measures of treatment effect can be calculated using the three year risk of a cardiovascular event with and without statin therapy (Fig. 5 ) [19]. The results can be compared to the five year risk of developing glaucoma with and without treatment in the Ocular Hypertension Treatment Study (Fig.…”
Section: Iop As a Risk Factormentioning
confidence: 99%